Skip to main content
TLPH
NASDAQ Life Sciences

CEO Angotti Vincent J. Buys $85K in Talphera Stock, Receives Significant Option Grant

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$0.777
Mkt Cap
$36.197M
52W Low
$0.38
52W High
$1.57
52W Position info
104% above low
Off High info
51% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

TLPH has more than doubled off its 52-week low of $0.38 on light trading volume (0.2× avg).

Summary

Talphera's CEO, Vincent J. Angotti, made an open market purchase of $85,587 in company stock and received a grant of 594,000 stock options, indicating strong insider conviction.


Key Events · Ownership and Investor Activity · TLPH

  • CEO Open Market Purchase

    CEO Vincent J. Angotti acquired 105,364 shares of common stock in an open market transaction valued at $85,587.18 on February 12, 2026.

  • Significant Option Grant

    The CEO was granted options to purchase 594,000 shares of common stock on February 12, 2026, with an exercise price of $0.8123, vesting over time to further align his interests with shareholders.

  • Ongoing Insider Accumulation

    This purchase contributes to a pattern of insider accumulation, with over $93,000 in net open market buys by three insiders in the last 90 days, signaling collective confidence.


Analysis · TLPH · Life Sciences

Talphera's CEO, Vincent J. Angotti, demonstrated strong conviction by making an open market purchase of over $85,000 in company stock. This direct investment, combined with a substantial grant of 594,000 stock options, significantly aligns his personal financial interests with the company's performance. This activity contributes to a broader pattern of insider accumulation, suggesting a positive internal outlook for the nano-cap company.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TLPH was trading at $0.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $36.2M. The 52-week trading range was $0.38 to $1.57. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TLPH - Latest Insights

TLPH
Nov 12, 2026, 5:11 PM EST
Filing Type: S-3
Importance Score:
8
Price at Filing: $1.02
Real-time Price: $0.8609 info
Change: -$0.1591 (-16%) info
Market Cap: $44.73M info
TLPH
Nov 12, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.03
Real-time Price: $0.8609 info
Change: -$0.1691 (-16%) info
Market Cap: $44.73M info
TLPH
Nov 12, 2026, 4:01 PM EST
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.04
Real-time Price: $0.8609 info
Change: -$0.1741 (-17%) info
Market Cap: $44.73M info
TLPH
Aug 12, 2026, 4:11 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.40
Real-time Price: $0.8609 info
Change: -$0.5391 (-39%) info
Market Cap: $44.73M info
TLPH
Aug 12, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.39
Real-time Price: $0.8609 info
Change: -$0.5291 (-38%) info
Market Cap: $44.73M info